[go: up one dir, main page]

MX2018004599A - Terapia de combinacion para el tratamiento de neoplasias malignas. - Google Patents

Terapia de combinacion para el tratamiento de neoplasias malignas.

Info

Publication number
MX2018004599A
MX2018004599A MX2018004599A MX2018004599A MX2018004599A MX 2018004599 A MX2018004599 A MX 2018004599A MX 2018004599 A MX2018004599 A MX 2018004599A MX 2018004599 A MX2018004599 A MX 2018004599A MX 2018004599 A MX2018004599 A MX 2018004599A
Authority
MX
Mexico
Prior art keywords
treatment
malignal
neoplasias
combination therapy
combination
Prior art date
Application number
MX2018004599A
Other languages
English (en)
Other versions
MX381582B (es
Inventor
Dimartino Jorge
V Agresta Samuel
Macbeth Kyle
Viswanadhan Krishnan
Saroj Kumar CHOPRA Vivek
douglas knight Robert
Xu Qiang
A Kenvin Laurie
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2018004599A publication Critical patent/MX2018004599A/es
Publication of MX381582B publication Critical patent/MX381582B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan métodos y composiciones para el tratamiento de cánceres en pacientes que portan una mutación de IDH2 a través de una combinación de un inhibidor de una enzima de IDH2 mutante y un agente desmetilante de ADN.
MX2018004599A 2015-10-15 2016-10-14 Terapia de combinacion para el tratamiento de neoplasias malignas. MX381582B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562242218P 2015-10-15 2015-10-15
PCT/US2016/057102 WO2017066611A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (2)

Publication Number Publication Date
MX2018004599A true MX2018004599A (es) 2018-09-21
MX381582B MX381582B (es) 2025-03-12

Family

ID=57219007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004599A MX381582B (es) 2015-10-15 2016-10-14 Terapia de combinacion para el tratamiento de neoplasias malignas.

Country Status (16)

Country Link
US (2) US10695352B2 (es)
EP (1) EP3362070B1 (es)
JP (1) JP6895956B2 (es)
KR (1) KR102701893B1 (es)
CN (1) CN108601787B (es)
AU (1) AU2016340098B2 (es)
BR (1) BR112018007447B1 (es)
CA (1) CA3002029A1 (es)
CL (1) CL2018000955A1 (es)
EA (1) EA036129B1 (es)
ES (1) ES2862730T3 (es)
IL (1) IL258580B (es)
MX (1) MX381582B (es)
SG (2) SG10201912869WA (es)
WO (1) WO2017066611A1 (es)
ZA (1) ZA201802420B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993172B2 (en) 2013-12-09 2018-06-12 Medtronic, Inc. Noninvasive cardiac therapy evaluation
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
KR20250065944A (ko) 2015-10-15 2025-05-13 르 라보레또레 쎄르비에르 악성종양을 치료하기 위한 복합 요법
IL258684B2 (en) 2015-10-15 2023-04-01 Agios Pharmaceuticals Inc Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh
CN108697698B (zh) * 2015-10-15 2021-12-03 阿吉奥斯制药公司 用于治疗恶性肿瘤的组合疗法
US11219769B2 (en) 2016-02-26 2022-01-11 Medtronic, Inc. Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing
CA3036053A1 (en) 2016-09-07 2018-03-15 Celgene Corporation Tablet compositions
ES2968376T3 (es) 2017-05-05 2024-05-09 Memorial Sloan Kettering Cancer Center Métodos de tratamiento de neoplasia mieloproliferativa
CN119280245A (zh) * 2017-06-12 2025-01-10 法国施维雅药厂 使用组合疗法治疗脑肿瘤的方法
KR20200027548A (ko) * 2017-07-09 2020-03-12 바이오사이트 리미티드 병용 암 요법
CN111902082B (zh) 2018-03-29 2025-03-07 美敦力公司 左心室辅助设备调整和评估
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US11697025B2 (en) 2019-03-29 2023-07-11 Medtronic, Inc. Cardiac conduction system capture
WO2020223351A1 (en) * 2019-04-29 2020-11-05 Immunogen, Inc. Therapeutic combinations comprising anti-cd123 immunoconjugates
EP3986404A1 (en) 2019-06-20 2022-04-27 Celgene Quanticel Research, Inc. Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US12201843B2 (en) 2019-10-09 2025-01-21 Medtronic, Inc. Synchronizing external electrical activity
US11497431B2 (en) 2019-10-09 2022-11-15 Medtronic, Inc. Systems and methods for configuring cardiac therapy
WO2021097160A1 (en) 2019-11-14 2021-05-20 Celgene Corporation Pediatric formulations for treatment of cancer
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途
WO2022192621A1 (en) * 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
EP4327888A3 (en) * 2008-05-15 2024-05-22 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
NZ589719A (en) * 2008-06-09 2012-08-31 Cyclacel Ltd Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
HK1201733A1 (en) * 2011-11-03 2015-09-11 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
RS57401B1 (sr) 2012-01-06 2018-09-28 Agios Pharmaceuticals Inc Terapeutski aktivna jedinjenja i postupci za njihovu upotrebu
JP6471155B2 (ja) 2013-07-11 2019-02-13 アギオス ファーマシューティカルス，インコーポレーテッド 癌の治療のためのｉｄｈ２変異体阻害剤としてのｎ，６−ビス（アリール又はヘテロアリール）−１，３，５−トリアジン−２，４−ジアミン化合物
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
TWI701242B (zh) 2013-08-02 2020-08-11 美商阿吉斯藥品股份有限公司 治療活性化合物及其使用方法(三)
WO2016053850A1 (en) 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN108349933A (zh) 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法
KR20250065944A (ko) 2015-10-15 2025-05-13 르 라보레또레 쎄르비에르 악성종양을 치료하기 위한 복합 요법
US20200268726A1 (en) 2015-12-04 2020-08-27 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
KR20180114202A (ko) 2016-02-26 2018-10-17 아지오스 파마슈티컬스 아이엔씨. 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제

Also Published As

Publication number Publication date
CA3002029A1 (en) 2017-04-20
SG10201912869WA (en) 2020-02-27
ES2862730T3 (es) 2021-10-07
ZA201802420B (en) 2020-08-26
EA201890961A1 (ru) 2018-11-30
US10695352B2 (en) 2020-06-30
KR20180064529A (ko) 2018-06-14
IL258580B (en) 2021-05-31
BR112018007447B1 (pt) 2023-12-05
CN108601787B (zh) 2022-07-29
EA036129B1 (ru) 2020-10-01
KR102701893B1 (ko) 2024-09-03
AU2016340098B2 (en) 2022-06-02
JP2018535951A (ja) 2018-12-06
US20210100805A1 (en) 2021-04-08
EP3362070A1 (en) 2018-08-22
EP3362070B1 (en) 2021-01-27
BR112018007447A2 (en) 2018-10-23
MX381582B (es) 2025-03-12
SG11201802964QA (en) 2018-05-30
US20180303840A1 (en) 2018-10-25
CN108601787A (zh) 2018-09-28
IL258580A (en) 2018-05-31
JP6895956B2 (ja) 2021-06-30
WO2017066611A1 (en) 2017-04-20
CL2018000955A1 (es) 2018-09-14
AU2016340098A1 (en) 2018-05-10
NZ741433A (en) 2024-07-26

Similar Documents

Publication Publication Date Title
MX2018004599A (es) Terapia de combinacion para el tratamiento de neoplasias malignas.
MX2018004586A (es) Terapia de combinacion para tratar tumores malignos.
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
MX2018004587A (es) Terapia de combinacion para tratar tumores malignos.
MX2018010252A (es) Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
CL2015002807A1 (es) Terapia de combinación
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
CL2018000927A1 (es) Terapia combinada para el tratamiento de neoplasias malignas
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2019013634A (es) Composiciones y metodos para tratar cancer con mutaciones de braf atipicas.
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2016016364A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MY187540A (en) Compounds active towards bromodomains
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX386249B (es) Terapia tusc2 para usarse en el tratamiento de cáncer.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MX2016012244A (es) Compuestos y sus metodos de uso.
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.